Journal of Nuclear Medicine: 62 (4)

April 1, 2021; Volume 62,Issue 4

Cover image

FEATURED ARTICLE

First-in-Humans Study of ⁶⁸Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1. Riikka Viitanen et al. See page 577.

PRRT in treatment-resistant meningioma: a scientifi c overview of targeted peptide-receptor radionuclide therapy in this challenging setting. Christian Mirian et al. See page 507.

TSPO PET with ¹⁸F-LW223: developing ¹⁸-kDa translocator proteins to detect macrophage-driven inflammation in myocardial infarction. Mark MacAskill et al. See page 536.

In this issue

Issue highlights

Quantification of Macrophage-Driven Inflammation During Myocardial Infarction with ¹⁸F-LW223, a Novel TSPO Radiotracer with Binding Independent of the rs6971 Human Polymorphism
First-in-Humans Study of ⁶⁸Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1
Somatostatin Receptor–Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis

⁶⁸Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Deep Learning Analysis of Upright-Supine High-Efficiency SPECT Myocardial Perfusion Imaging for Prediction of Obstructive Coronary Artery Disease: A Multicenter Study
Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Diagnostic Evaluation of Pulmonary Embolism During the COVID-19 Pandemic

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to